FDA Approves Valproate for Bipolar Disorder, Seizures, and Migraine Headaches
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Valproate for Bipolar Disorder, Seizures, and Migraine Headaches

NEW YORK -- July 30, 2008 -- The US Food and Drug Administration (FDA) has approved valproic acid (Stavzor) delayed-release capsules in 125-, 250-, and 500-mg strengths.

"The small size and soft gel capsule formulation of valproate should make this new product easy to swallow, which in my experience is critical to helping valproate patients start, and stay on, their medication," said Miguel Martelli, MD, a psychiatrist in private practice in Saint Marys, Georgia.

Valproate products should not be administered to patients with hepatic disease or significant hepatic dysfunction. In a clinical trial of valproate in elderly patients with dementia, some patients experienced somnolence, sometimes requiring discontinuation.

Cases of life-threatening pancreatitis, some rapidly progressing to death, have been reported in both adults and children receiving valproate. Valproate is contraindicated in patients with known urea cycle disorders. Administration of valproic acid and topiramate has been associated with hyperammonaemia, with and without encephalopathy.

Common adverse events (>5% incidence) associated with valproate in clinical studies were nausea, somnolence, dizziness, vomiting, asthenia, abdominal pain, dyspepsia, rash, diarrhoea, increased appetite, tremour, weight gain, back pain, alopecia, headache, fever, anorexia, constipation, diplopia, amblyopia/blurred vision, ataxia, nystagmus, emotional lability, thinking abnormal, amnesia, flu syndrome, infection, bronchitis, rhinitis, thrombocytopenia, ecchymosis, peripheral oedema, insomnia, nervousness, depression, pharyngitis, dyspnea, and tinnitus.

SOURCE: Noven Therapeutics, LLC

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities